Loading…

Ossotide promotes cell differentiation of human osteoblasts from osteogenesis imperfecta patients by up-regulating miR-145

Abstract Ossotide as an effective bone formation compound preparation has been proved to promote osteoblasts differentiation. MiR-145 is significantly decreased in osteogenesis imperfecta (OI) patients, but it is still unknown whether ossotide performed its effect by regulating miR-145. In this stud...

Full description

Saved in:
Bibliographic Details
Published in:Biomedicine & pharmacotherapy 2016-10, Vol.83, p.1105-1110
Main Authors: Sun, Keming, Wang, Junjian, Liu, Fangna, Ji, Zejuan, Guo, Zhanhao, Zhang, Chunxu, Yao, Manye
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c417t-e8ce9542b6053c402989de78d968f395ad1c63c7284a5ce3a1a90554fbb995ff3
cites cdi_FETCH-LOGICAL-c417t-e8ce9542b6053c402989de78d968f395ad1c63c7284a5ce3a1a90554fbb995ff3
container_end_page 1110
container_issue
container_start_page 1105
container_title Biomedicine & pharmacotherapy
container_volume 83
creator Sun, Keming
Wang, Junjian
Liu, Fangna
Ji, Zejuan
Guo, Zhanhao
Zhang, Chunxu
Yao, Manye
description Abstract Ossotide as an effective bone formation compound preparation has been proved to promote osteoblasts differentiation. MiR-145 is significantly decreased in osteogenesis imperfecta (OI) patients, but it is still unknown whether ossotide performed its effect by regulating miR-145. In this study, we investigated the effect of ossotide on regulating miR-145 expression and osteoblasts differentiation. The primary osteoblasts cells were isolated from OI patients and then cultured with different concentrations (0, 25, 50, 100, 200 μg/l) of ossotide. The cell proliferation was detected with CCK-8 Elisa kit after ossotide treatment. The level of miR-145 expression was determined using qRT-PCR. In order to study whether ossotide up regulated miR-145, miR-145 mimic and miR-145 inhibitor were used to up regulate and down regulate the miR-145 levels in osteoblasts. The expressions of Runx2, Osx, β-catenin, TCF-1 were detected using Western blot and qRT-PCR. We observed that miR-145 was up regulated by ossotide treatment in miR-145 mimic or miR-145 inhibitor treated osteoblasts. What’s more, up regulated miR-145 increased the expression of osteoblasts differentiation regulated protein Runx2 and Osx. In addition, Wnt signaling related β-catenin, TCF-1 were activated by up-regulated miR-145 which was induced by ossotide treatment. In summary, ossotide induced cell differentiation and Wnt signaling activation in osteoblasts by up regulating miR-145.
doi_str_mv 10.1016/j.biopha.2016.08.025
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1835532046</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>1_s2_0_S0753332216307284</els_id><sourcerecordid>1835532046</sourcerecordid><originalsourceid>FETCH-LOGICAL-c417t-e8ce9542b6053c402989de78d968f395ad1c63c7284a5ce3a1a90554fbb995ff3</originalsourceid><addsrcrecordid>eNqFkUtv1TAQhS0EoreFf4CQl2wS_Ijz2CChqkClSpV4rC3HGd_6ksTB4yBdfj2OUliwYeXx6JwZnW8IecVZyRmv357K3oflwZQi_0rWlkyoJ-TAO8WKmrHmKTmwRslCSiEuyCXiiTGmatk-JxeiUYo3qj6QX_eIIfkB6BLDFBIgtTCOdPDOQYQ5eZN8mGlw9GGdTC4wQehHgwmpy5a9cYQZ0CP10wLRgU2GLtmY_Uj7M12XIsJxHXNrPtLJfy54pV6QZ86MCC8f3yvy7cPN1-tPxd39x9vr93eFrXiTCmgtdKoSfc2UtBUTXdsN0LRDV7dOdsoM3NbSNqKtjLIgDTcdU6pyfd91yjl5Rd7sc3PCHytg0pPHLaSZIayoeSuVkoJVdZZWu9TGgBjB6SX6ycSz5kxv1PVJ79T1Rl2zVmfq2fb6ccPaTzD8Nf3BnAXvdgHknD89RI02w7Ew-Jhh6SH4_234d4Ad_eytGb_DGfAU1jhnhpprFJrpL9vlt8PzWrKNjPwN2DOsKA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1835532046</pqid></control><display><type>article</type><title>Ossotide promotes cell differentiation of human osteoblasts from osteogenesis imperfecta patients by up-regulating miR-145</title><source>Elsevier</source><creator>Sun, Keming ; Wang, Junjian ; Liu, Fangna ; Ji, Zejuan ; Guo, Zhanhao ; Zhang, Chunxu ; Yao, Manye</creator><creatorcontrib>Sun, Keming ; Wang, Junjian ; Liu, Fangna ; Ji, Zejuan ; Guo, Zhanhao ; Zhang, Chunxu ; Yao, Manye</creatorcontrib><description>Abstract Ossotide as an effective bone formation compound preparation has been proved to promote osteoblasts differentiation. MiR-145 is significantly decreased in osteogenesis imperfecta (OI) patients, but it is still unknown whether ossotide performed its effect by regulating miR-145. In this study, we investigated the effect of ossotide on regulating miR-145 expression and osteoblasts differentiation. The primary osteoblasts cells were isolated from OI patients and then cultured with different concentrations (0, 25, 50, 100, 200 μg/l) of ossotide. The cell proliferation was detected with CCK-8 Elisa kit after ossotide treatment. The level of miR-145 expression was determined using qRT-PCR. In order to study whether ossotide up regulated miR-145, miR-145 mimic and miR-145 inhibitor were used to up regulate and down regulate the miR-145 levels in osteoblasts. The expressions of Runx2, Osx, β-catenin, TCF-1 were detected using Western blot and qRT-PCR. We observed that miR-145 was up regulated by ossotide treatment in miR-145 mimic or miR-145 inhibitor treated osteoblasts. What’s more, up regulated miR-145 increased the expression of osteoblasts differentiation regulated protein Runx2 and Osx. In addition, Wnt signaling related β-catenin, TCF-1 were activated by up-regulated miR-145 which was induced by ossotide treatment. In summary, ossotide induced cell differentiation and Wnt signaling activation in osteoblasts by up regulating miR-145.</description><identifier>ISSN: 0753-3322</identifier><identifier>EISSN: 1950-6007</identifier><identifier>DOI: 10.1016/j.biopha.2016.08.025</identifier><identifier>PMID: 27551756</identifier><language>eng</language><publisher>France: Elsevier Masson SAS</publisher><subject>Case-Control Studies ; Cell Differentiation - drug effects ; Cell Proliferation - drug effects ; Complex Mixtures - pharmacology ; Core Binding Factor Alpha 1 Subunit - genetics ; Core Binding Factor Alpha 1 Subunit - metabolism ; Differentiation ; Disease Progression ; Down-Regulation - drug effects ; Humans ; Internal Medicine ; Medical Education ; MicroRNAs - genetics ; MicroRNAs - metabolism ; MiR-145 ; Ossotide ; Osteoblasts ; Osteoblasts - drug effects ; Osteoblasts - metabolism ; Osteoblasts - pathology ; Osteogenesis Imperfecta - genetics ; Osteogenesis Imperfecta - pathology ; Runx2 ; Up-Regulation - drug effects ; Up-Regulation - genetics ; Wnt Signaling Pathway - drug effects</subject><ispartof>Biomedicine &amp; pharmacotherapy, 2016-10, Vol.83, p.1105-1110</ispartof><rights>Elsevier Masson SAS</rights><rights>2016 Elsevier Masson SAS</rights><rights>Copyright © 2016 Elsevier Masson SAS. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c417t-e8ce9542b6053c402989de78d968f395ad1c63c7284a5ce3a1a90554fbb995ff3</citedby><cites>FETCH-LOGICAL-c417t-e8ce9542b6053c402989de78d968f395ad1c63c7284a5ce3a1a90554fbb995ff3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27551756$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Sun, Keming</creatorcontrib><creatorcontrib>Wang, Junjian</creatorcontrib><creatorcontrib>Liu, Fangna</creatorcontrib><creatorcontrib>Ji, Zejuan</creatorcontrib><creatorcontrib>Guo, Zhanhao</creatorcontrib><creatorcontrib>Zhang, Chunxu</creatorcontrib><creatorcontrib>Yao, Manye</creatorcontrib><title>Ossotide promotes cell differentiation of human osteoblasts from osteogenesis imperfecta patients by up-regulating miR-145</title><title>Biomedicine &amp; pharmacotherapy</title><addtitle>Biomed Pharmacother</addtitle><description>Abstract Ossotide as an effective bone formation compound preparation has been proved to promote osteoblasts differentiation. MiR-145 is significantly decreased in osteogenesis imperfecta (OI) patients, but it is still unknown whether ossotide performed its effect by regulating miR-145. In this study, we investigated the effect of ossotide on regulating miR-145 expression and osteoblasts differentiation. The primary osteoblasts cells were isolated from OI patients and then cultured with different concentrations (0, 25, 50, 100, 200 μg/l) of ossotide. The cell proliferation was detected with CCK-8 Elisa kit after ossotide treatment. The level of miR-145 expression was determined using qRT-PCR. In order to study whether ossotide up regulated miR-145, miR-145 mimic and miR-145 inhibitor were used to up regulate and down regulate the miR-145 levels in osteoblasts. The expressions of Runx2, Osx, β-catenin, TCF-1 were detected using Western blot and qRT-PCR. We observed that miR-145 was up regulated by ossotide treatment in miR-145 mimic or miR-145 inhibitor treated osteoblasts. What’s more, up regulated miR-145 increased the expression of osteoblasts differentiation regulated protein Runx2 and Osx. In addition, Wnt signaling related β-catenin, TCF-1 were activated by up-regulated miR-145 which was induced by ossotide treatment. In summary, ossotide induced cell differentiation and Wnt signaling activation in osteoblasts by up regulating miR-145.</description><subject>Case-Control Studies</subject><subject>Cell Differentiation - drug effects</subject><subject>Cell Proliferation - drug effects</subject><subject>Complex Mixtures - pharmacology</subject><subject>Core Binding Factor Alpha 1 Subunit - genetics</subject><subject>Core Binding Factor Alpha 1 Subunit - metabolism</subject><subject>Differentiation</subject><subject>Disease Progression</subject><subject>Down-Regulation - drug effects</subject><subject>Humans</subject><subject>Internal Medicine</subject><subject>Medical Education</subject><subject>MicroRNAs - genetics</subject><subject>MicroRNAs - metabolism</subject><subject>MiR-145</subject><subject>Ossotide</subject><subject>Osteoblasts</subject><subject>Osteoblasts - drug effects</subject><subject>Osteoblasts - metabolism</subject><subject>Osteoblasts - pathology</subject><subject>Osteogenesis Imperfecta - genetics</subject><subject>Osteogenesis Imperfecta - pathology</subject><subject>Runx2</subject><subject>Up-Regulation - drug effects</subject><subject>Up-Regulation - genetics</subject><subject>Wnt Signaling Pathway - drug effects</subject><issn>0753-3322</issn><issn>1950-6007</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><recordid>eNqFkUtv1TAQhS0EoreFf4CQl2wS_Ijz2CChqkClSpV4rC3HGd_6ksTB4yBdfj2OUliwYeXx6JwZnW8IecVZyRmv357K3oflwZQi_0rWlkyoJ-TAO8WKmrHmKTmwRslCSiEuyCXiiTGmatk-JxeiUYo3qj6QX_eIIfkB6BLDFBIgtTCOdPDOQYQ5eZN8mGlw9GGdTC4wQehHgwmpy5a9cYQZ0CP10wLRgU2GLtmY_Uj7M12XIsJxHXNrPtLJfy54pV6QZ86MCC8f3yvy7cPN1-tPxd39x9vr93eFrXiTCmgtdKoSfc2UtBUTXdsN0LRDV7dOdsoM3NbSNqKtjLIgDTcdU6pyfd91yjl5Rd7sc3PCHytg0pPHLaSZIayoeSuVkoJVdZZWu9TGgBjB6SX6ycSz5kxv1PVJ79T1Rl2zVmfq2fb6ccPaTzD8Nf3BnAXvdgHknD89RI02w7Ew-Jhh6SH4_234d4Ad_eytGb_DGfAU1jhnhpprFJrpL9vlt8PzWrKNjPwN2DOsKA</recordid><startdate>20161001</startdate><enddate>20161001</enddate><creator>Sun, Keming</creator><creator>Wang, Junjian</creator><creator>Liu, Fangna</creator><creator>Ji, Zejuan</creator><creator>Guo, Zhanhao</creator><creator>Zhang, Chunxu</creator><creator>Yao, Manye</creator><general>Elsevier Masson SAS</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20161001</creationdate><title>Ossotide promotes cell differentiation of human osteoblasts from osteogenesis imperfecta patients by up-regulating miR-145</title><author>Sun, Keming ; Wang, Junjian ; Liu, Fangna ; Ji, Zejuan ; Guo, Zhanhao ; Zhang, Chunxu ; Yao, Manye</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c417t-e8ce9542b6053c402989de78d968f395ad1c63c7284a5ce3a1a90554fbb995ff3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Case-Control Studies</topic><topic>Cell Differentiation - drug effects</topic><topic>Cell Proliferation - drug effects</topic><topic>Complex Mixtures - pharmacology</topic><topic>Core Binding Factor Alpha 1 Subunit - genetics</topic><topic>Core Binding Factor Alpha 1 Subunit - metabolism</topic><topic>Differentiation</topic><topic>Disease Progression</topic><topic>Down-Regulation - drug effects</topic><topic>Humans</topic><topic>Internal Medicine</topic><topic>Medical Education</topic><topic>MicroRNAs - genetics</topic><topic>MicroRNAs - metabolism</topic><topic>MiR-145</topic><topic>Ossotide</topic><topic>Osteoblasts</topic><topic>Osteoblasts - drug effects</topic><topic>Osteoblasts - metabolism</topic><topic>Osteoblasts - pathology</topic><topic>Osteogenesis Imperfecta - genetics</topic><topic>Osteogenesis Imperfecta - pathology</topic><topic>Runx2</topic><topic>Up-Regulation - drug effects</topic><topic>Up-Regulation - genetics</topic><topic>Wnt Signaling Pathway - drug effects</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Sun, Keming</creatorcontrib><creatorcontrib>Wang, Junjian</creatorcontrib><creatorcontrib>Liu, Fangna</creatorcontrib><creatorcontrib>Ji, Zejuan</creatorcontrib><creatorcontrib>Guo, Zhanhao</creatorcontrib><creatorcontrib>Zhang, Chunxu</creatorcontrib><creatorcontrib>Yao, Manye</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Biomedicine &amp; pharmacotherapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Sun, Keming</au><au>Wang, Junjian</au><au>Liu, Fangna</au><au>Ji, Zejuan</au><au>Guo, Zhanhao</au><au>Zhang, Chunxu</au><au>Yao, Manye</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Ossotide promotes cell differentiation of human osteoblasts from osteogenesis imperfecta patients by up-regulating miR-145</atitle><jtitle>Biomedicine &amp; pharmacotherapy</jtitle><addtitle>Biomed Pharmacother</addtitle><date>2016-10-01</date><risdate>2016</risdate><volume>83</volume><spage>1105</spage><epage>1110</epage><pages>1105-1110</pages><issn>0753-3322</issn><eissn>1950-6007</eissn><abstract>Abstract Ossotide as an effective bone formation compound preparation has been proved to promote osteoblasts differentiation. MiR-145 is significantly decreased in osteogenesis imperfecta (OI) patients, but it is still unknown whether ossotide performed its effect by regulating miR-145. In this study, we investigated the effect of ossotide on regulating miR-145 expression and osteoblasts differentiation. The primary osteoblasts cells were isolated from OI patients and then cultured with different concentrations (0, 25, 50, 100, 200 μg/l) of ossotide. The cell proliferation was detected with CCK-8 Elisa kit after ossotide treatment. The level of miR-145 expression was determined using qRT-PCR. In order to study whether ossotide up regulated miR-145, miR-145 mimic and miR-145 inhibitor were used to up regulate and down regulate the miR-145 levels in osteoblasts. The expressions of Runx2, Osx, β-catenin, TCF-1 were detected using Western blot and qRT-PCR. We observed that miR-145 was up regulated by ossotide treatment in miR-145 mimic or miR-145 inhibitor treated osteoblasts. What’s more, up regulated miR-145 increased the expression of osteoblasts differentiation regulated protein Runx2 and Osx. In addition, Wnt signaling related β-catenin, TCF-1 were activated by up-regulated miR-145 which was induced by ossotide treatment. In summary, ossotide induced cell differentiation and Wnt signaling activation in osteoblasts by up regulating miR-145.</abstract><cop>France</cop><pub>Elsevier Masson SAS</pub><pmid>27551756</pmid><doi>10.1016/j.biopha.2016.08.025</doi><tpages>6</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0753-3322
ispartof Biomedicine & pharmacotherapy, 2016-10, Vol.83, p.1105-1110
issn 0753-3322
1950-6007
language eng
recordid cdi_proquest_miscellaneous_1835532046
source Elsevier
subjects Case-Control Studies
Cell Differentiation - drug effects
Cell Proliferation - drug effects
Complex Mixtures - pharmacology
Core Binding Factor Alpha 1 Subunit - genetics
Core Binding Factor Alpha 1 Subunit - metabolism
Differentiation
Disease Progression
Down-Regulation - drug effects
Humans
Internal Medicine
Medical Education
MicroRNAs - genetics
MicroRNAs - metabolism
MiR-145
Ossotide
Osteoblasts
Osteoblasts - drug effects
Osteoblasts - metabolism
Osteoblasts - pathology
Osteogenesis Imperfecta - genetics
Osteogenesis Imperfecta - pathology
Runx2
Up-Regulation - drug effects
Up-Regulation - genetics
Wnt Signaling Pathway - drug effects
title Ossotide promotes cell differentiation of human osteoblasts from osteogenesis imperfecta patients by up-regulating miR-145
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-30T03%3A31%3A50IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Ossotide%20promotes%20cell%20differentiation%20of%20human%20osteoblasts%20from%20osteogenesis%20imperfecta%20patients%20by%20up-regulating%20miR-145&rft.jtitle=Biomedicine%20&%20pharmacotherapy&rft.au=Sun,%20Keming&rft.date=2016-10-01&rft.volume=83&rft.spage=1105&rft.epage=1110&rft.pages=1105-1110&rft.issn=0753-3322&rft.eissn=1950-6007&rft_id=info:doi/10.1016/j.biopha.2016.08.025&rft_dat=%3Cproquest_cross%3E1835532046%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c417t-e8ce9542b6053c402989de78d968f395ad1c63c7284a5ce3a1a90554fbb995ff3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1835532046&rft_id=info:pmid/27551756&rfr_iscdi=true